# Diabetic Peripheral Neuropathic Pain FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetic-peripheral-neuropathic-pain

> 10 upcoming FDA catalysts in diabetic Peripheral Neuropathic Pain: JOURNAVX (suzetrigine, VRTX) on Jan to Apr 2027 (topline data readout); JOURNAVX (suzetrigine, VRTX) on January 2027 (primary completion); VX-993 (VRTX) on Mar to Jun 2027 (topline data readout); VX-993 (VRTX) on March 2027 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan to Apr 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06696443 (Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696443)) |
| January 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06696443 (Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696443)) |
| Mar to Jun 2027 | [VX-993 topline data readout](https://sec-api.dev/pdufa/vx-993) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06619860 (Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619860)) |
| March 2027 | [VX-993 primary completion](https://sec-api.dev/pdufa/vx-993) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06619860 (Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619860)) |
| Apr to Jul 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07231419 (Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07231419)) |
| April 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07231419 (Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07231419)) |
| May to Aug 2027 | [JOURNAVX (suzetrigine) topline data readout](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06628908 (Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628908)) |
| May 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06628908 (Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628908)) |
| July 2027 | [LY4065967 primary completion](https://sec-api.dev/pdufa/ly4065967) | LLY | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07285018 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285018)) |
| Jul to Oct 2027 | [LY4065967 topline data readout](https://sec-api.dev/pdufa/ly4065967) | LLY | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07285018 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285018)) |

## Drugs

- [JOURNAVX (suzetrigine)](https://sec-api.dev/pdufa/suzetrigine) (VRTX)
- [VX-993](https://sec-api.dev/pdufa/vx-993) (VRTX)
- [LY4065967](https://sec-api.dev/pdufa/ly4065967) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetic-peripheral-neuropathic-pain.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetic Peripheral Neuropathic Pain FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetic-peripheral-neuropathic-pain

```bibtex
@misc{secapidev_indications_diabetic_peripheral_neuropathic_pain_20261116,
  title        = {Diabetic Peripheral Neuropathic Pain FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetic-peripheral-neuropathic-pain}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetic_peripheral_neuropathic_pain_20261116","title":"Diabetic Peripheral Neuropathic Pain FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetic-peripheral-neuropathic-pain","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
